Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 37147298

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Nat Commun
Publication date
2023 May 5
First author
Berko ER

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Berko ER
      type
      Author
    2. name
      Witek GM
      type
      Author
    3. name
      Matkar S
      type
      Author
    4. name
      Petrova ZO
      type
      Author
    5. name
      Wu MA
      type
      Author
    6. name
      Smith CM
      type
      Author
    7. name
      Daniels A
      type
      Author
    8. name
      Kalna J
      type
      Author
    9. name
      Kennedy A
      type
      Author
    10. name
      Gostuski I
      type
      Author
    11. name
      Casey C
      type
      Author
    12. name
      Krytska K
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Berko ER
      type
      Author
    2. name
      Witek GM
      type
      Author
    3. name
      Matkar S
      type
      Author
    4. name
      Petrova ZO
      type
      Author
    5. name
      Wu MA
      type
      Author
    6. name
      Smith CM
      type
      Author
    7. name
      Daniels A
      type
      Author
    8. name
      Kalna J
      type
      Author
    9. name
      Kennedy A
      type
      Author
    10. name
      Gostuski I
      type
      Author
    11. name
      Casey C
      type
      Author
    12. name
      Krytska K
      type
      Author
    bibliography ids
    1. nci-bib-4d2cdabed0896ef08177abec
    book metadata
    content sha256
    8e4817b6ceba856f25d54ce086f45cfada800222255672e0ab97ff3c0946c68e
    document type
    citation
    dois
    1. 10.1038/s41467-023-38195-0
    electronic publication date
    display
    2023 May 5
    precision
    day
    year
    2023
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:37147298
    immutable id
    pubmed:37147298@8e4817b6ceba856f25d54ce086f45cfada800222255672e0ab97ff3c0946c68e
    journal
    abbreviation
    Nat Commun
    issn electronic
    2041-1723
    issn print
    Source null
    issue
    1
    name
    Nature communications
    nlm unique id
    101528555
    pages
    2601
    volume
    14
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      37147298
      provenance
      batch id
      5329a5d0877ee70ecd11
      provider
      NCBI PubMed ESummary
      record sha256
      b7c3afd3b66b2c2142fc2c0bf2d1d5545aaa533db8a5014fb51152fa98c79beb
      response sha256
      bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
      retrieved at
      2026-09-09T23:48:15.763286+00:00
      publication date
      display
      2023 May 5
      precision
      day
      year
      2023
      publication types
      1. Journal Article
      2. Research Support, N.I.H., Extramural
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/37147298/
      title
      Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.

      Preserved source evidence · Independent clinical review pending · Not medical advice